Ronquest NA, Paret K, Gould I, Barnett CL, Mladsi (she/her) DM. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports. J Manag Care Spec Pharm. 2021 Nov;27(11):1601-12. doi: 10.18553/jmcp.2021.27.11.1601
Herring WL, Mladsi DM. Equal value of life-years gained: comparison of methodologies for a cohort Markov model. Poster presented at the Virtual ISPOR 2021 Conference; May 2021. [abstract] Value Health. 2021 Jun; 24(Suppl 1):S176.
Gandola AE, Ait Sarkouh R, Orfanos P, Bouisset F, Licitra L, Bourhis J, Mladsi D, Chirila C, Paret K, Barnett C. An early cost-effectiveness analysis of xevinapant in combination with chemo-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck in United States. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.
Ronquest N, Paret K, Gould I, Barnett CL, Mladsi D. Effects of stakeholder engagement with Icer on cost-effectiveness of new interventions: lessons learned from a critical review of evaluations from 2018 to 2019. Presented at the Virtual ISPOR 2021 Conference; May 2021.
Mader G, Mladsi (she/her) D, Zhou X, Sanon M, Wang J, Willey C, Seliger S. Racial differences in mortality rates among elderly Non-ESRD CKD and ESRD patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): study findings using data from the USRDS. Poster presented at the Virtual National Kidney Foundation 2021 Spring Clinical Meetings; April 2021.